Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 10:32 PM ET

Biotechnology

Company Overview of Infinity Pharmaceuticals, Inc.

Company Overview

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at ...

780 Memorial Drive

Cambridge, MA 02139

United States

195 Employees

Phone:

617-453-1000

Fax:

617-453-1001

Key Executives for Infinity Pharmaceuticals, Inc.

Chairman of The Board, Chief Executive Officer and President
Age: 55
Total Annual Compensation: $568.5K
Chief Financial Officer, Chief Business Officer, Executive Vice President and Treasurer
Age: 49
Total Annual Compensation: $390.0K
President of Research & Development
Age: 60
Total Annual Compensation: $479.5K
Chief Medical Officer and Executive Vice President
Age: 52
Total Annual Compensation: $647.1K
Chief Scientific Officer and Executive Vice President
Age: 52
Total Annual Compensation: $381.0K
Compensation as of Fiscal Year 2014.

Infinity Pharmaceuticals, Inc. Key Developments

Infinity Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Infinity Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, loss from operations was $38,592,000 against $35,222,000 a year ago. Net loss was $38,428,000 $0.78 per basic and diluted share against $38,024,000 $0.78 per basic and diluted share a year ago. Collaboration revenue was $4,880,000. For the six months, loss from operations was $131,206,000 against $76,517,000 a year ago. Net loss was $131,730,000 $2.69 per basic and diluted share against $80,290,000 $1.66 per basic and diluted share a year ago. Collaboration revenue was $9,244,000.

Infinity Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Infinity Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Infinity Pharmaceuticals, Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015

Infinity Pharmaceuticals, Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015 . Venue: Boston, Massachusetts, United States.

Similar Private Companies By Industry

Company Name Region
Phloronol, Inc. United States
Sabik Medical Inc. United States
Alpine Biosciences, Inc. United States
Immunomatrix, Inc. United States
Fe3 Medical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Infinity Pharmaceuticals, Inc., please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.